CF
SYRE icon

Corebridge Financial’s Spyre Therapeutics SYRE Stock Holding History

Corebridge Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,595
Closed -$316K – 2478
2025
Q1 		$316K Buy
19,595
+2,382
+14% +$49.6K ﹤0.01% 1825
2024
Q4 		$401K Sell
17,213
-1,299
-7% -$38.1K ﹤0.01% 1797
2024
Q3 		$544K Sell
18,512
-113
-0.6% -$3.15K ﹤0.01% 1688
2024
Q2 		$438K Buy
+18,625
New +$628K ﹤0.01% 1763

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Corebridge Financial's SYRE Position: Q2 2025 in Review

Corebridge Financial sold out of Spyre Therapeutics (SYRE) in Q2 2025, closing a stake of 19,595 shares — an estimated $316K sold.

Corebridge Financial first reported a position in SYRE in Q2 2024 and held it in 4 quarters. The position peaked at $544K in Q3 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • Corebridge Financial reported no remaining Spyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 19,595 Spyre Therapeutics shares in Q2 2025, an estimated $316K.
  • Corebridge Financial first reported a position in Spyre Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Spyre Therapeutics position peaked at $544K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.